Cannabis-Europe-Companies-Aurora


Updated December 1, 2020


Positioning

Aurora was founded in Alberta, Canada in 2016 as a licensed producer of medical cannabis. In the time since its origination, Aurora has quickly expanded into the Canadian adult-use market and various international medical markets.

Aurora supplies medical cannabis to a number of key European markets, such as Germany, Italy, UK, Denmark and Poland. Aurora Deutschland is a major supplier of medical cannabis to Germany, and in 2019 was one of only three cannabis companies to receive regulatory approval from the German government to begin cultivation in the country (expected to begin 2021), granting them five lots with a total annual expected capacity of at least 1,000 kg. In July 2019, Aurora won a bid to deliver medical cannabis to the Italian government with a minimum of 400 kilograms exported from Canada over two years. Their cannabis is imported via Aurora Deutschland and then delivered to Italy where it is sold to the Ministry of Defense for distribution.

In addition, Aurora has a 100,000 square-foot retrofit greenhouse called Nordic 1 in Denmark, which has the ability to produce 8,000 kilograms of cannabis annually. The company announced in June 2020 that it would “immediately ramp up cannabis production" at the facility because it "believes it can adequately service the European market with EU-GMP certified product" from Nordic 1. Local production at this scale is expected to help the company maintain a strong competitive presence in the region as it lowers the cost of supply.

Products

Aurora Deutschland distributes cannabis flower and extracts to the German medical market. Aurora Nordic is authorized to sell the only softgel permitted through the Danish medical pilot program: Sedamen. Though Aurora Nordic does not provide images or details of their products, they produce and sell both tinctures and flower across Europe. In 2019, four varieties of cannabis flower distributed by Aurora Deutschland were approved for sale in Poland, with the first sales beginning in Q4 of that year. Though unnamed, they contain varying cannabinoid levels:

  • THC ≤1%, CBD 12%

  • THC 8%, CBD 8%

  • THC 20%, CBD ≤1%

  • THC 22%, CBD ≤1%

Footprint

Aurora has one European production facility located in Denmark, which is run by the company's majority-owned joint venture Aurora Nordic, with first sales from the location beginning last year. European facilities include Aurora Nordic 1, a 100,000-square-foot retrofit greenhouse with a 8,000-kilogram annual capacity, and Aurora Nordic 2, a one-million square foot greenhouse - though the facility's construction and completion are currently on hold.

 

Aurora also has sales or operations in the following European countries: Czech Republic, Denmark, Estonia, France, Germany, Greece, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Spain, and the United Kingdom. Aurora's principal European markets are Germany, Denmark, Italy, and Poland.

Source: Brightfield Group 2020

Strengths and Opportunities

Strengths
  • Strong established presence throughout the region
  • Operational European cultivation facilities located in Denmark
  • One of only three coveted German domestic cultivation licenses
Opportunities
  • Completion of Aurora Nordic 2 in order to expand cultivation capacity
  • Expansion of product types, volume where already established

Recent News


If you just created a page please go back to customfields and edit the page type accordingly.